India Ratings and Research (Ind-Ra) has said the 10.3 per cent year-on-year growth of India's pharmaceutical market during March was led by volume growth of 1.6 per cent, price growth of 5.1 per cent and products launches at 3.6 per cent.
The growth was attributed to acute therapy products primarily in anti-infective, gastro and vitamins segments.
But the growth was 2 per cent lower than Ind-Ra's earlier estimates due to a higher-than-estimated impact of lockdowns and local restrictions on acute therapy products.
"However, we estimate the market growth to rebound to 8 to 10 per cent during FY22 as we have started witnessing higher sales of acute therapy products partially aided by lower base impact of FY21."
During 4Q FY21, the pharmaceutical market grew 5.3 per cent led by a volume decline of 2.4 per cent, price growth of 5 per cent and products launches at 2.7 per cent. On moving average total (MAT) for the past 12 months, the growth was 2.1 per cent for March 2021.
Acute therapies such as gastro and vitamins witnessed sales growth of 21.6 per cent and 22.2 per cent respectively while anti-infectives grew 8.5 per cent yoy during March 2021.
Growth underperformance was observed in chronic therapies during the month with cardiac and anti-diabetic growing 6.3 per cent and 0.3 per cent respectively.
However, on a moving average total March 2021 basis, a growth outperformance was observed across these therapies.
Cipla, Glenmark and Aristo significantly outperformed the market with growth of 7.5 per cent, 15.2 per cent and 6.8 per cent.
This was led by higher sales of COVID-19 related products and the continued outperformance of chronic therapies, said Ind-Ra.
.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU